Home MedTech & BioTech CorVista Health secures CAD 65M in Series C funding

CorVista Health secures CAD 65M in Series C funding

Canada

CorVista Health secures CAD 65M in Series C funding
CorVista Health secures CAD 65M in Series C funding

Toronto-based healthtech startup CorVista Health (formerly known as Analytics 4 Life) announced in March 2021 that it has raised CAD 65M in a Series C round led by Ambix Life Science and participation from MedVenture Partners.

The latest round brings CorVista Health’s total funding raised to date to US$ 100M.

The startup plans to use the proceeds from the funding round to develop its point-of-care cardiac diagnostic platform and CorVista System and invest in clinical research.

About the startup

CorVista Health

CorVista Health was founded in 2012 and offers an AI-powered platform that enables physicians to rapidly perform tests for heart disease. CEO Don Crawford said there has never been a more significant need for point-of-care diagnostic modalities that provide rapid cardiac patients testing. He added that the latest round of funding has put them in a position to offer help with the ongoing healthcare crisis by providing physicians with a non-invasive solution for heart disease diagnosis.

The startup applies machine learning and AI to real-time test data and aims to revolutionise cardiovascular care and the patient experience. It claims that its solution enables physicians to evaluate heart function without any radiation, contrast agents, injections, fasting, or exercise.

In December 2020, Analytics 4 Life renamed itself to CorVista Health and hired Scott Burger as its chief commercial officer and vice president. Burger led the startup’s rebranding, which CorVista said replicated its progress from an early-stage medtech startup to a digital health company.

CorVista Health also plans to advance its clinical research, which will help its platform perform checks for coronary artery disease, as well as elevated left ventricular end-diastolic pressure and elevated mean pulmonary artery pressure, which it calls hallmarks of heart failure and pulmonary hypertension, respectively.

Words from the investors

Peter Townshend, managing member of Ambix Venture Management said his firm believes the CorVista System has the capability to reduce the burden on both patients and the healthcare system. He also added that CorVista Health has the potential to transform the way heart disease is diagnosed and managed.

Previously, the startup had raised US$ 25M in a Series B funding round held in 2017.

We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!

Next Story

Previous articleSnapcommerce bags CAD 107M in funding
Next articleSan Francisco based cryptocurrency platform Eco raises US $ 26 million
Aishwarya writes about the startup ecosystem on VCBay. She is a third-year Computer Science engineering student who looks forward to exploring the world of startups and finance.

3 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here